It is made available under a CC-BY 4.0 International license .

1 Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

3	Sarah E. Messiah, PhD, MPH ^{a,b} , Frances Brito, MS ^c , Harold W. Kohl, III, PhD, MSPH ^{d,e} , Stacia
4	DeSantis, PhD ^c , Melissa Valerio-Shewmaker, PhD ^f , Jessica Ross, BSc, Michael D. Swartz,
5	PhD ^c , Ashraf Yaseen, PhD ^c , Steven H. Kelder, PhD, MPH ^d , Shiming Zhang, MS ^c , Onyinye S
6	Omega-Njemnobi, MD, PhD ^d , Michael O. Gonzalez, MPH ^c , Leqing Wu, MS ^c , Eric Boerwinkle,
7	PhD ^c , David Lakey, M ^g , Jennifer A. Shuford, MD ^h , Stephen J. Pont, MD ^h
8	
9	Affiliations: "The University of Texas Health Science Center at Houston, School of Public
10	Health in Dallas, Dallas, TX, USA; ^b Center for Pediatric Population Health, The University of
11	Texas Health Science Center at Houston, School of Public Health and Children's Health System
12	of Texas, Dallas, TX, USA; "The University of Texas Health Science Center at Houston, School
13	of Public Health in Houston, Houston, TX, USA; ^d The University of Texas Health Science
14	Center at Houston, School of Public Health in Austin, Austin, TX, USA; University of Texas at
15	Austin, Austin, TX, USA; ^f The University of Texas Health Science Center at Houston, School of
16	Public Health in Brownsville, Brownsville, TX, USA; ^g The University of Texas System, Austin,
17	TX, USA; hTexas Department of State Health Services, Austin, TX, USA
18	
19	Address correspondence to: Sarah E. Messiah, The University of Texas Health Science Center
20	at Houston, School of Public Health in Dallas, 2777 N Stemmons Fwy, Dallas, TX
21	(Sarah.E.Messiah@uth.tmc.edu), 972-546-2919
22 23	Short title: SARS-CoV-2 Antibody Durability from Natural Infection
23 24	Short the. SARS-Cov-2 Antroody Durability from Natural Infection
25	Conflict of Interest Disclosures (includes financial disclosures): We have no disclosures to
26	report, financial or otherwise
27	1 /
28	Funding Support: Texas Department of State Health Services (Contract #HHS000866600001).
29	
30	Role of Funder: The Texas Department of State Health Services (DSHS) had no role in the
31	study design, data collection and analysis. Drs. Pont and Shuford are DSHS collaborators on this
32	project. They assisted in the interpretation of data, in the writing of this report, and in the
33	decision to submit this paper for publication.
34	
35	Clinical Trials Registration: N/A
36	
37	
38	
39	
40	
41	
42	
43	
44	

It is made available under a CC-BY 4.0 International license .

see manuscript DOI for details

45 Abbreviations:

- 46
- 47 COVID-19: coronavirus disease 2019
- 48 **DSHS:** Department of State Health Services
- 49 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 50 Texas CARES: Texas COVID-19 Antibody Response Survey
- 51
- 52
- 53
- 54

It is made available under a CC-BY 4.0 International license .

Contributors' Statement Page

- Drs. Boerwinkle, Lakey, Pont, Shuford, and Valerio-Shewmaker conceptualized and designed
- the Texas CARES study.
- Dr. Messiah drafted the initial manuscript and reviewed and revised the manuscript based on all other authors input.
- Drs. Shewmaker, Kohl and Kelder and Jessica Ross designed the data collection instruments and
- collected data. Michael Gonzalez programmed all survey questions in REDCap.
- Frances Brito carried out the initial analyses and reviewed and revised the manuscript. Drs.
- DeSantis, Swartz and Yaseen reviewed all analyses.
- Leqing Wu, Shiming Zhang and Dr. Omega-Njemnobi coordinated and supervised data
- collection, and critically reviewed the manuscript for important intellectual content.
- and agree to see manuscript Dol for of All authors approved the final manuscript as submitted and agree to be accountable for all
- aspects of the work.

It is made available under a CC-BY 4.0 International license .

85

Abstract

- **Background.** Recent data suggest the SARS-CoV-2 Delta (B.1.617.2) variant is more
- transmissible among children compared to the Alpha (B.1.1.7) variant. The true incidence and
- 88 longitudinal presence of antibody response to SARS-CoV-2 infection is not known, however.
- 89 We provided estimates of antibody response using Texas Coronavirus Antibody REsponse
- 90 Survey (Texas CARES) data, a prospective population-based seroprevalence project designed to
- assess antibody status over time among the general population throughout the state.
- 92 Methods. In October 2020 Texas CARES began enrolling adults (aged 20-80 years) and children
- 93 (aged 5-19 years). Participants were offered a series of three SARS-CoV-2 antibody tests over 6-
- 8 months, or every 2-3 months that includes the immunoassay for detection of antibodies to the
- 95 SARS-CoV-2 nucleocapsid protein (Roche N-test). Descriptive characteristics and COVID-19
- 96 infection-related symptom status was determined by questionnaire at the time of enrollment and
- 97 prior to each successive blood draw. This analysis included participants ages 5-to-19 years old
- 98 who have completed all three antibody assessments.
- **Results.** From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of
- 100 nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later
- 101 (mean 7.0 months, SD 0.97). There was no difference in the presence of antibodies by symptom
- status (asymptotic versus symptomatic) or severity (mild-moderate versus severe), sex, age
- 103 group, or body mass index group (underweight, healthy weight, overweight, obesity) over the 104 three antibody measurement timepoints.
- 105 **Conclusions.** These results suggest that infection-induced antibodies persist and thus may
- 106 provide some protection against future infection for at least half a year. 57.9% of the sample
- 107 were negative for infection-induced antibodies at their third measurement point, suggesting a
- 108 significant proportion of children have still not acquired natural infection.
- 109
- 110

111

112

113

114

115

116

It is made available under a CC-BY 4.0 International license .

118 Introduction

119	As of November 11, 2021 more than 6.6 million children in the United States have tested
120	positive for COVID-19. ¹ In early September, child COVID-19 cases peaked at 252,000 new
121	cased per week and have declined since but remain extremely high. Since the first week of
122	September, there have been almost 1.5 million additional child cases. ¹ These recent data suggest
123	the delta (B.1.617.2) variant is more transmissible among children compared to the alpha (
124	B.1.1.7) variant. ¹ These data are particularly troubling as they coincide with school openings
125	across the country. Information about the durability of SARS-CoV-2-specific natural immune
126	responses in children is important to inform school-and community-based transmission
127	mitigation and pediatric vaccination strategies. However, the true incidence and longitudinal
128	presence of antibody response to SARS-CoV-2 infection is not known in the pediatric population
129	due to the high proportion of asymptomatic infection ² and prioritization of testing for adults and
130	those with severe illness early in the pandemic.

131 Methods

The Texas Coronavirus Antibody REsponse Survey (Texas CARES) is an ongoing prospective 132 population-based seroprevalence project designed to assess antibody status over time among a 133 volunteer population throughout the state. The design of Texas CARES has been described 134 previously^{2,3,4} but briefly, includes adults (aged 20-80 years) and children (aged 5-19 years). 135 Texas CARES enrollment commenced in October 2020. Participants ages 5-to-19 years were 136 recruited from large pediatric healthcare systems, Federally Qualified Healthcare Centers, urban 137 and rural pediatric and family medicine practices, health insurance providers, and a social media 138 139 campaign throughout the state of Texas. Participants were offered a series of three SARS-CoV-2 antibody tests over 6-8 months, or every 2-3 months, that includes the immunoassay for 140

It is made available under a CC-BY 4.0 International license .

detection of antibodies to the SARS-CoV-2 nucleocapsid protein (Roche N-test). The 141 nucleocapsid test uses whole blood and has a sensitivity and specificity exceeding 97%.^{5,6} 142 Descriptive characteristics and COVID-19 infection-related symptom status were determined by 143 questionnaire at the time of enrollment and prior to each successive blood draw. This analysis 144 included participants ages 5-to-19 years old who have completed all three antibody assessments. 145 The presence of SARS-CoV-2 nucleocapsid protein antibodies across the three test timepoints 146 was explored via generalized linear mixed models with a logit link. Random effects for each 147 participant were univariately fit. A likelihood ratio test was performed comparing each model to 148 the intercept-only model to obtain a p-value. All protocols were reviewed and approved by the 149 University of Texas Health Science Center's Committee for the Protection of Human Subjects, 150 but also deemed public health practice by the Texas Department of State Health Services IRB. 151 see man

Results 152

From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of 153 154 nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later (mean 7.0 months, SD 0.97). Two children seroconverted from positive to negative status 155 between their first and second antibody test. Ten children seroconverted from negative to 156 positive between their first and second antibody test, and six between their second and third tests, 157 respectively. There was no difference in the presence of antibodies by symptom status 158 159 (asymptotic versus symptomatic) or severity (mild-moderate versus severe), sex, age group, or body mass index group (underweight, healthy weight, overweight, obesity) over the three 160 antibody measurement timepoints. (Table 1) 161

162 N-test values to detect the presence of IgM, IgG, or IgA antibodies increased from baseline to

timepoint two and then decreased by the third immunoassay assessment. The subsequent 163

It is made available under a CC-BY 4.0 International license .

downward trend was significant between timepoints 1 and 3 (P=0.007) and timepoints 2 and 3 (P<0.001) (Figure 1).

166 **Discussion**

167	The data reported here show that the majority of children followed for > six months and
168	who had three successive antibody test results available for analysis retained SARS-CoV-2
169	antibodies over the entire time period regardless of age, sex, COVID-19 symptom status and
170	severity, and body mass index. These results suggest that infection-induced antibodies persist
171	and thus may provide some protection against future infection for at least half a year. We were
172	unable to confirm COVID-19 infection prior to the baseline assessment, thus these data cannot
173	confirm durability beyond six months. It should also be noted that well over half (57.9%) of the
174	sample were negative for infection-induced antibodies at their third measurement point,
175	suggesting a significant proportion of children are still immune-naïve to SARS-CoV-2 due to
176	natural infection. As such, vaccines have an important role to play in providing protection
177	against COVID-19 for children aged 12 years and older, and for those < 12 years as they become
178	eligible.

179

It is made available under a CC-BY 4.0 International license.

Acknowledgements: 181

This work was supported by the Texas Department of State Health Services and the University 182

of Texas System. We would like to acknowledge the University of Texas Health Science Center 183

- at Houston, School of Public Health's Texas CARES investigative team for their contribution to 184
- participant recruitment, data collection, statistical analysis, and data visualization including 185
- 186 Sarah E Messiah, PhD; Melissa Valerio-Shewmaker, PhD, MPH; Steven Kelder, PhD, MPH;
- Harold W Kohl, PhD; Kimberly Aguillard, DrPH; Michael Swartz, PhD; Stacia DeSantis, PhD; 187
- Ashraf Yaseen, PhD; Luis León-Novelo, PhD; Eric Boerwinkle, PhD; Jessica Ross, BS; Frances 188
- Brito, MS; Michael Gonzalez, MS; Leqing Wu, PhD; Onyinye Omega Niemnobi, MBBS, MPH; 189
- Shiming Zhang, MS; Joy Yoo, BS; Tianyao Hao, MS; Cesar Pinzon Gomez, MD; Karina Farias, 190
- BA; Ashleigh Gil, MPH; David Lakey, MD; Jennifer Shuford, MD, MPH; Stephen Pont, MD, 191
- MPH. This analysis would not have been possible without the partnership of many. 192
- 193
- The TX CARES investigation team would like to thank Children's Health System of Texas, 194
- Dallas, TX; Cook Children's Forth Worth, TX; Covenant Health, Lubbock, TX; Driscoll 195
- Children's, Corpus Christi, TX; El Paso Children's, El Paso, TX; UTHealth McGovern, 196
- Houston, TX; UTHealthRGV, Rio Grande Valley, TX; UTHealth Tyler, Tyler, TX; Ascension 197
- Health, Privia Health, Superior Health Plan, TX Association of Family Physicians, TX Medical 198
- Association, TX Pediatric Society, and Federally Qualified Health Care Centers statewide, for 199
- assisting with sharing information with families about this survey. 200
- 201 202

Data Sharing Statement Manu' 203

- Texas CARES investigators are committed to data sharing. Granular results and user-specified 204 data summaries are currently publicly available on the Texas CARES portal 205
- (https://sph.uth.edu/projects/texascares/dashboard). When baseline recruitment is complete, a 206
- deidentified individual level dataset will be available for download from the same portal. 207
- 208
- 209
- 210

211

212

213

214

215

216

217

It is made available under a CC-BY 4.0 International license .

219 **References**

220	1.	American Academy of Pediatrics and the Children's Hospital Association. Children and
221		COVID-19: State Data Report. https://www.aap.org/en/pages/2019-novel-coronavirus-
222		covid-19-infections/children-and-covid-19-state-level-data-report/ Accessed November
223		12, 2021.
224	2.	Messiah SE, Valerio-Shewmaker MA, DeSantis, SM, et al. Estimated Prevalence of
225		SARS-CoV-2 Antibodies in the Texas Pediatric Population, 2021. Preprints with the
226	•	Lancet. Available at SSRN: <u>http://dx.doi.org/10.2139/ssrn.3868061</u>
227	3.	Valerio-Shewmaker MA, DeSantis SM, et al. Strategies to estimate prevalence of SARS-
228		CoV-2 antibodies in a Texas vulnerable population: results from phase I of the Texas
229		Coronavirus Antibody REsponse Survey (TX CARES). medRxiv [Preprint]. 2021 Jul
230		medRxiv doi: https://doi.org/10.1101/2021.08.04.21261613
231	4.	DeSantis SM, León-Novelo LG, Swartz MD, et al. Estimation of total immunity to
232		SARS-Cov-2 in Texas. medRxiv [Preprint]. 2021 medRxiv doi:
233	_	https://doi.org/10.1101/2021.08.05 21261610
234	5.	Roche. Elecsys® Anti-SARS-CoV-2. Package Insert 2020-07, V9.0; Material Numbers
235		09203095190 and 09203079190. US Food and Drug Administration
236		https://www.fda.gov/media/137605/download
237	6.	Roche. Elecsys® Anti-SARS-CoV-2 S. Package Insert 2020-12, V1.0; Material
238		Numbers 09289267190 and 09289275190. US Food and Drug Administration
239		https://www.fda.gov/media/144037/download
240		500
241		
241		
242		
243		
244		
244		
245		
246		
247		
248		
240		
249		
250		
251		
251		
252		
253		

It is made available under a CC-BY 4.0 International license .

Table 1. Sars-CoV-2 antibody status over 3 timepoints (each separated by 2-3 months) by

255 symptom status and severity and descriptive characteristics.

256

	Timepoint 1 (N=159)		Timepoint 2 (N=159)		Timepoint 3 (N=159)		p-value ^a
	Positive	Negative	Positive	Negative	Positive	Negative	
	53 (33.3%)	106 (66.6%)	61 (38.4%)	98 (61.6%)	67 (42.1%)	92 (57.9%)	
Symptom Status	· · · · ·	, , , , , , , , , , , , , , , , , , ,			· · · · · · · · · · · · · · · · · · ·		0.498
Symptomatic	25 (50.0%)	30 (29.4%)	26 (44.8%)	29 (30.9%)	26 (40.6%)	29 (33.0%)	
Asymptomatic	25 (50.0%)	72 (70.6%)	32 (55.2%)	65 (69.1%)	38 (59.4%)	59 (67.0%)	
Missing	3	4	3	4	3	4	
Symptom Severity ^b							0.872
Mild-Moderate	21 (87.5%)	24 (80.0%)	21 (84.0%)	24 (82.8%)	21 (84.0%)	24 (82.8%)	
Severe	3 (12.5%)	6 (20.0%)	4 (16.0%)	5 (17.2%)	4 (16.0%)	5 (17.2%)	
Sex							0.942
Males	22 (42.3%)	43 (40.6%)	25 (41.7%)	40 (40.8%)	28 (42.4%)	37 (40.2%)	
Females	30 (57.7%)	63 (59.4%)	35 (58.3%)	58 (59.2%)	38 (57.6%)	55 (59.8%)	
Age Group				26	Tan		0.977
5-9 years	15 (28.3%)	23 (21.7%)	16 (26.2%)	22 (22.4%)	17 (25.4%)	21 (22.8%)	
10-14 years	20 (37.7%)	48 (45.3%)	25 (41.0%)	43 (43.9%)	30 (44.8%)	38 (41.3%)	
15-19 years	18 (34.0%)	35 (33.0%)	20 (32.8%)	33 (33.7%)	20 (29.9%)	33 (35.9%)	
Body Mass Index Group ^c							
Underweight	1 (2.1%)	4 (4.0%)	1 (1.8%)	4 (4.3%)	2 (3.3%)	3 (3.4%)	
Healthy	31 (64.6%)	66 (65.3%)	37 (66.1%)	60 (64.5%)	40 (65.6%)	57 (64.8%)	
Overweight	8 (16.7%)	21 (20.8%)	10 (17.9%)	19 (20.4%)	11 (18.0%)	18 (20.5%)	
Obesity	S 8(16.7%)	10 (9.9%)	8 (14.3%)	10 (10.8%)	8 (13.1%)	10 (11.4%)	
Missing	5	5	5	5	6	4	

257


- ^ap value calculated from likelihood ratio test
- 259 ^bPercent of symptomatic children total
- ^cBased on standardized body mass index percentiles adjusted for age and sex
- 261 (https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm)

262


263

- 265
- 266
- 267
- 268
- 269
- 270

It is made available under a CC-BY 4.0 International license .



Distribution of Positive N-Test Values at Each Time Point



Boxplot for the N-test values across the three timepoints for the sample that were positive at the first timepoint (N=53). The N-test value denotes prior COVID-19 infection. Each box represents data falling between the 25th and the 75th percentiles. The horizontal bar within the box represents the median, and the whiskers extend 1.5 times the interquartile range below the 25th and above the 75th percentiles, and the points that lie beyond the whiskers can be considered extreme values.

P values calculated by Wilcoxon Signed Rank test. Note that this is not a test for the difference in medians, but
rather a non-parametric test for differences in sets of pairs.

*significant at the p=0.05 level

280